PIPELINE WATCH – Eight Approvals, Two CRLs And A Breakthrough
This article was originally published in Scrip
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.